Spots Global Cancer Trial Database for Study of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients
Official Title: Randomized Controlled Trial of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients Receiving Etoposide Combined With Platinum Based First-line Chemotherapy
Study ID: NCT02039518
Conditions
Study Description
Brief Summary: The purpose of this study is to Evaluate and compare safety and efficacy of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients Receiving Etoposide Combined With Platinum Based First-line Chemotherapy
Detailed Description: from the first cycle of treatment (day one) to two month after the last cycle
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer hospital Fudan University, Shanghai, Shanghai, China
Contact Details
Name: WU X HUA, DOCTOR
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
